Tempus AI announces strategic collaboration with Bristol Myers

Tempus AI (TEM) announced a new initiative with Bristol Myers Squibb (BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success across five initial clinical trial programs. “Our collaboration with BMS aims to optimize clinical development by peering deeper into patient biology than ever before,” said Ryan Fukushima, CEO of Data and Apps at Tempus. “Our multimodal data library allows us to connect the dots between clinical records and molecular subtypes. Together, we are doing more than just generating insights. We are uncovering the hidden biological signals of unmet patient need, which allows us to assess trial assumptions and stratify patient groups with unprecedented precision. We are moving past traditional approaches and creating a new level of data-driven confidence in the drug development process.”

Claim 55% Off TipRanks